Inferra AI / Company / OBX
Obsidian Therapeutics, Inc.
OBX · Health Care
Last earnings Aug 14, 2026
AI analysis
Q1 2026 · reported Aug 3, 2026
Based on: Earnings release + parent 8-K — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
Accordingly, until such time as we can generate significant revenue from sales of OBX-115 or any future product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.
Until such time, if ever, as we can generate substantial product revenue to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, potentially including collaborations, licenses, and other similar arrangements.
Event summary
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Unless the context otherwise requires, references in this section to we, us, our and the Company refer to Obsidian
Based on: Earnings release + parent 8-K — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Accordingly, until such time as we can generate significant revenue from sales of OBX-115 or any future product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Until such time, if ever, as we can generate substantial product revenue to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, potentially including collaborations, licenses, and other similar arrangements.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market OBX-115 and any future product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
11 Stock-Based Compensation We measure stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant recognized using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected fair value of our common stock, the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Strategy & priorities
This discussion and analysis and other parts of this Current Report on Form 8-K contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies, objectives, expectations, intentions and beliefs.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Our proprietary cytoDRiVE platform is highly versatile and allows us to leverage drug responsive domains to control protein function, with our initial focus on TIL cell therapies developed from this platform, or cytoTILs .
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Since inception, we have incurred significant operating losses and negative cash flows from operations, reflecting our primary focus on advancing our research and development programs, building our platform, and supporting early-stage clinical and preclinical activities.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
The collaboration focused on developing TIL containing regulated mbIL15 with the potential to enhance anti-tumor efficacy and reduce tumor burden in patients suffering from different types of solid tumors.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Risks & headwinds
This discussion and analysis and other parts of this Current Report on Form 8-K contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies, objectives, expectations, intentions and beliefs.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
However, our forecast for the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Anderson License Agreement may be terminated by the Board of Regents upon notice for an uncured challenge of the Board of Regents patents and by mutual agreement of us and the Board of Regents.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
The assumptions underlying these valuations were highly complex and subjective and represented management s best estimates, which involved inherent uncertainties and the application of management s judgment.
SEC original ↗Obsidian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
3 documentsEarnings releases
7 documentsPresentations
0 documentsNo presentations for Obsidian Therapeutics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Obsidian Therapeutics, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Obsidian Therapeutics, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“… …determined using the binomial lattice model. The key assumptions used in the model are OBX stock price, dividend yield, expected future volatility of OBX stock, credit risk-adjusted discounting rate, risk-free rate,… …Net revenue (Note 18) 105,782”
See also the earnings calendar for every tracked company’s next earnings date.